Acute and chronic effect of bariatric surgery on circulating autotaxin levels

Physiol Rep. 2019 Mar;7(5):e14004. doi: 10.14814/phy2.14004.

Abstract

Autotaxin (ATX), an adipose tissue-derived lysophospholipase, has been involved in the pathophysiology of cardiometabolic diseases. The impact of bariatric surgery on circulating ATX levels is unknown. We examined the short- (24 h, 5 days) and longer-term (6 and 12 months) impact of bariatric surgery; as well as the short-term effect of caloric restriction (CR) on plasma ATX levels in patients with severe obesity. We measured ATX levels in 69 men and women (mean age: 41 ± 11 years, body mass index: 49.8 ± 7.1 kg/m2 ), before and after biliopancreatic diversion with duodenal switch surgery (BPD-DS) as well as in a control group (patients with severe obesity without surgery; n = 34). We also measured ATX levels in seven patients with severe obesity and type 2 diabetes who underwent a 3-day CR protocol before their BPD-DS. At baseline, ATX levels were positively associated with body mass index, fat mass, insulin resistance (HOMA-IR) as well as insulin and leptin levels and negatively with fat-free mass. ATX concentrations decreased 26.2% at 24 h after BPD-DS (342.9 ± 152.3 pg/mL to 253.2 ± 68.9 pg/mL, P < 0.0001) and by 16.4% at 12 months after BPD-DS (342.9 ± 152.3 pg/mL to 286.8 ± 182.6 pg/mL, P = 0.04). ATX concentrations were unchanged during follow-up in the control group (P = 0.4), and not influenced by short-term CR. In patients with severe obesity, bariatric surgery induced a rapid and sustained decrease in plasma ATX levels. Acute changes in ATX may not be explained by bariatric surgery-induced CR.

Keywords: Autotaxin; bariatric surgery; caloric restriction; obesity; sex.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity
  • Adult
  • Bariatric Surgery* / adverse effects
  • Biomarkers / blood
  • Body Mass Index
  • Caloric Restriction
  • Case-Control Studies
  • Down-Regulation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / diagnosis
  • Obesity / physiopathology
  • Obesity / surgery*
  • Phosphoric Diester Hydrolases / blood*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome
  • Weight Loss

Substances

  • Biomarkers
  • Phosphoric Diester Hydrolases
  • alkylglycerophosphoethanolamine phosphodiesterase

Grants and funding